What Are Cancer Drugs?

Cancer drugs are pharmacological agents used to kill, slow the growth of, or inhibit the spread of malignant cells within the body. They span a wide spectrum of mechanisms: broad cytotoxic compounds that target all rapidly dividing cells, narrow-spectrum agents that inhibit a specific mutated protein driving a particular tumor type, and biological agents that recruit or augment the patient's own immune system. The selection of a drug or combination regimen depends on the tumor's histology, stage, and molecular profile, as well as the patient's performance status and organ function.

The field of cancer pharmacology traces its roots to observations during World War I that sulfur mustard compounds caused bone marrow suppression, which led directly to the use of nitrogen mustard as the first chemotherapy agent for lymphoma in the 1940s. Since then, drug development has moved from largely empirical screening of cytotoxic compounds toward rational design of agents targeting specific oncoproteins identified through genomic analysis.

Cytotoxic Chemotherapy

Cytotoxic chemotherapy agents disrupt cell division by damaging DNA or interfering with the mitotic machinery. Alkylating agents, including cyclophosphamide and cisplatin, form covalent cross-links in DNA strands, blocking replication. Antimetabolites such as methotrexate and 5-fluorouracil compete with normal metabolic substrates required for nucleotide synthesis. Topoisomerase inhibitors, including doxorubicin and irinotecan, trap DNA-topoisomerase complexes, producing lethal strand breaks. Because these agents act on all rapidly dividing cells, they cause predictable toxicities in the bone marrow, gastrointestinal epithelium, and hair follicles. As reviewed in a review of cancer chemotherapy and drug resistance mechanisms, acquired resistance through efflux pump upregulation, target mutation, and DNA repair pathway activation remains the principal limitation of cytotoxic regimens.

Targeted Therapy

Targeted therapies exploit specific molecular alterations present in tumor cells but absent or less active in normal tissue. Small-molecule kinase inhibitors are the largest class: imatinib blocks the BCR-ABL fusion kinase driving chronic myeloid leukemia, erlotinib and gefitinib inhibit mutant EGFR in lung adenocarcinoma, and vemurafenib targets the BRAF V600E mutation in melanoma. Monoclonal antibodies represent another major category; trastuzumab binds HER2-amplified breast cancer cells, while bevacizumab neutralizes VEGF to restrict tumor angiogenesis. The NCI targeted therapies resource notes that targeted agents generally produce fewer off-target toxicities than cytotoxic drugs but are vulnerable to resistance arising from secondary mutations or activation of bypass signaling pathways.

Immunotherapy and Biological Agents

Immunotherapy recruits or restores immune surveillance to recognize and destroy tumor cells. Immune checkpoint inhibitors, including antibodies against PD-1 (pembrolizumab, nivolumab), PD-L1 (atezolizumab), and CTLA-4 (ipilimumab), block inhibitory signals that cancer cells exploit to suppress T-cell activity. CAR-T cell therapy genetically engineers a patient's own T cells to express chimeric antigen receptors targeting tumor surface markers such as CD19 in B-cell malignancies. Bispecific antibodies simultaneously bind a tumor antigen and a T-cell receptor, physically linking immune cells to tumor cells. The NCI immunotherapy overview describes how durable responses, sometimes exceeding ten years in melanoma and lung cancer, have been documented with checkpoint inhibition, though only a fraction of patients respond and immune-related adverse events can affect any organ system.

Applications

Cancer drugs have applications in a range of fields, including:

• First-line and salvage treatment of hematologic malignancies
• Neoadjuvant and adjuvant therapy alongside surgery and radiation
• Palliative treatment to reduce tumor burden and extend survival
• Drug delivery research using nanoparticles and conjugated antibodies
• Combination regimens with radiotherapy as radiosensitizing agents